bluuebunny/crossref_metadata_2025_split huggingface dataset:
A Clinical Prediction Rule for the Severity of Congenital Diaphragmatic Hernias in Newborns
Authors: Brindle Mary Elizabeth , Cook Earl Francis , Tibboel Dick , Lally Pamela A. , Lally Kevin P. 
Published: July 2014

BACKGROUND:
Congenital diaphragmatic hernia (CDH) is a condition with a highly variable outcome. Some infants have a relatively mild disease process, whereas others have significant pulmonary hypoplasia and hypertension. Identifying high-risk infants postnatally may allow for targeted therapy.

METHODS:
Data were obtained on 2202 infants from the Congenital Diaphragmatic Hernia Study Group database from January 2007 to October 2011. Using binary baseline predictors generated from birth weight, 5-minute Apgar score, congenital heart anomalies, and chromosome anomalies, as well as echocardiographic evidence of pulmonary hypertension, a clinical prediction rule was developed on a randomly selected subset of the data by using a backward selection algorithm. An integer-based clinical prediction rule was created. The performance of the model was validated by using the remaining data in terms of calibration and discrimination.

RESULTS:
The final model included the following predictors: very low birth weight, absent or low 5-minute Apgar score, presence of chromosomal or major cardiac anomaly, and suprasystemic pulmonary hypertension. This model discriminated between a population at high risk of death (∼50%) intermediate risk (∼20%), or low risk (&lt;10%). The model performed well, with a C statistic of 0.806 in the derivation set and 0.769 in the validation set and good calibration (Hosmer-Lemeshow test, P = .2).

CONCLUSIONS:
A simple, generalizable scoring system was developed for CDH that can be calculated rapidly at the bedside. Using this model, intermediate- and high-risk infants could be selected for transfer to high-volume centers while infants at highest risk could be considered for advanced medical therapies.
Weighted Blankets and Sleep in Autistic Children—A Randomized Controlled Trial
Authors: Gringras Paul , Green Dido , Wright Barry , Rush Carla , Sparrowhawk Masako , Pratt Karen , Allgar Victoria , Hooke Naomi , Moore Danielle , Zaiwalla Zenobia , Wiggs Luci 
Published: July 2014

OBJECTIVE:
To assess the effectiveness of a weighted-blanket intervention in treating severe sleep problems in children with autism spectrum disorder (ASD).

METHODS:
This phase III trial was a randomized, placebo-controlled crossover design. Participants were aged between 5 years and 16 years 10 months, with a confirmed ASD diagnosis and severe sleep problems, refractory to community-based interventions. The interventions were either a commercially available weighted blanket or otherwise identical usual weight blanket (control), introduced at bedtime; each was used for a 2-week period before crossover to the other blanket. Primary outcome was total sleep time (TST) recorded by actigraphy over each 2-week period. Secondary outcomes included actigraphically recorded sleep-onset latency, sleep efficiency, assessments of child behavior, family functioning, and adverse events. Sleep was also measured by using parent-report diaries.

RESULTS:
Seventy-three children were randomized and analysis conducted on 67 children who completed the study. Using objective measures, the weighted blanket, compared with the control blanket, did not increase TST as measured by actigraphy and adjusted for baseline TST. There were no group differences in any other objective or subjective measure of sleep, including behavioral outcomes. On subjective preference measures, parents and children favored the weighted blanket.

CONCLUSIONS:
The use of a weighted blanket did not help children with ASD sleep for a longer period of time, fall asleep significantly faster, or wake less often. However, the weighted blanket was favored by children and parents, and blankets were well tolerated over this period.
Atopic Dermatitis, Melatonin, and Sleep Disturbance
Authors: Chang Yung-Sen , Chou Yen-Ting , Lee Jyh-Hong , Lee Pei-Lin , Dai Yang-Shia , Sun Chi , Lin Yu-Tsan , Wang Li-Chieh , Yu Hsin-Hui , Yang Yao-Hsu , Chen Chun-An , Wan Kong-Sang , Chiang Bor-Luen 
Published: July 2014

BACKGROUND AND OBJECTIVES:
Sleep disturbance is common in patients with atopic dermatitis (AD). However, studies have largely been questionnaire-based, and the pathophysiology remains unclear. The aims of this study were to determine objective characteristics of sleep disturbance in children with AD and explore contributing factors and clinical predictors.

METHODS:
Sleep parameters were measured by actigraphy and polysomnography in 72 patients with AD and 32 controls ages 1 to 18 years. Urinary 6-sulfatoxymelatonin levels, serum cytokines, and total and allergen-specific immunoglobulin E (IgE) levels were also measured.

RESULTS:
The patients with AD had significantly reduced sleep efficiency, longer sleep onset latency, more sleep fragmentation, and less nonrapid eye movement sleep. Results from actigraphy correlated well with those from polysomnography. The AD disease severity was associated with sleep disturbance (r = 0.55−0.7), and a Scoring Atopic Dermatitis index of ≥48.7 predicted poor sleep efficiency with a sensitivity of 83.3% and a specificity of 75% (area under the curve = 0.81, P = .001). Lower nocturnal melatonin secretion was significantly associated with sleep disturbance in the patients with AD. Other correlates of sleep disturbance included pruritus, scratching movements, higher total serum IgE levels, and allergic sensitization to dust mite and staphylococcal enterotoxins.

CONCLUSIONS:
Poor sleep efficiency is common in children with AD and can be predicted by the Scoring Atopic Dermatitis index. Melatonin and IgE might play a role in the sleep disturbance. Further studies are required to explore the mechanisms and clinical implications, and actigraphy could serve as a useful evaluating tool.
No Motion without Emotion: Getting Started with Hard Facts on a Soft Topic
Authors: Gröppel-Klein Andrea 
Published: July 2014

Abstract
The power of emotions is evident in almost all areas of marketing and consumer behavior. Consumers often strive for "affect optimization": At the end of the day, they want their emotional balance to be positive. That means products, advertisements and other people - anything that can make us happy - all have a high potential for success. Hundreds of empirical studies demonstrate the importance of emotions in marketing and consumer behavior. But emotions are very diverse and can be researched from different perspectives. Methods for measuring emotions are as diverse as the various theoretical approaches. They range from verbal self-evaluation and picture-based scales to neuroscientific measures like heart rate, electrodermal reactions or regional brain response. Other popular approaches include observational methods that attempt to capture emotional facial expressions. Which method fits best needs to be decided on a case-by-case basis.
Stressed Out: How Stress Develops and How to Cope with it
Authors: Mortillaro Marcello , Scherer Klaus R. 
Published: July 2014

Abstract
Our experience of stress depends on how we evaluate the circumstances impacting our individual well-being. In principle, any event can be a stressor. Certain events can produce complex emotional states, such as a mixture of anger and worry. If such states are prolonged, they can lead to stress. Stress can be identified by means of such expressive components as facial expression and signs of stress in the voice. Indeed, the voice is particularly sensitive to stress and is frequently used to measure stress levels. Coping strategies differ from person to person and are not mutually exclusive. Often, people use multiple strategies at the same time. Not all of these strategies are good for individual well-being or favor a cooperation-based work culture. To avoid employee burnout, companies should keep an eye on the stress load of their employees and develop trainings to increase emotional competences and improve constructive stress management.
Feels Right … Go Ahead? When to Trust Your Feelings in Judgments and Decisions
Authors: Tuan Pham Michel 
Published: July 2014

Abstract
Not only are subjective feelings an integral part of many judgments and decisions, they can even lead to improved decisions and better predictions. Individuals who have learned to trust their feelings performed better in economic-negotiation games than their rational-thinking opponents. But emotions are not just relevant in negotiations and decisions. They also play a decisive role in forecasting future events. Candidates who trusted their feelings made better predictions than people with less emotional confidence. Emotions contain valuable information about the world around us. This information is not as readily available in our mind as hard facts but rather lies in the background of our conscious attention. In negotiation situations like the ultimatum game, feelings provide an intuitive sense of what offer is about right and what offer is too high or too low. But feelings also summarize statistical relationships among things that, on the surface, may seem disconnected. These statistical relationships make more probable futures feel more right than less probable futures. However, researchers warn that you should not always trust your feelings. Feelings that tend to help are those based on general knowledge, not those based on easy-to-verbalize local knowledge.
Breaking Up is Hard to Do: The Ups and Downs of Divorcing Brands
Authors: Fournier Susan 
Published: July 2014

Abstract
Relationships with brands are like relationships between people. Even when they were very close, they can fail for diverse reasons. The disadoption of favorite brands doesn't happen overnight. It tends to be an extended, often painful process and not a clear-cut, one-off event. Breakups are not isolated to the person and the brand. Friends and family often get involved and offer their opinions and advice. Other brand relationships are also affected by the disconnection, and this can speed up or delay the process of breaking up. The brand relationship changes its form and can go from being a best friend to a platonic love, a distant friend, a stalker or even an enemy. A breakup is never the end of the relationship. Rather, it redefines the relationship and is part of a never-ending cycle of change. If the former relationship is perceived positively, it is easier to eventually activate and intensify it. If negative aspects prevail, negative word of mouth is a danger and companies must be able to counter it. Some relationships reach a point of no return. But there are also customers who might regret having abandoned a brand. With some sensitivity, it might be possible to win them back.
There´s No Passion; I Need Passion: Why Some Brands Excite Consumers So Much
Authors: Hemetsberger Andrea 
Published: July 2014

Abstract
Not all brands have the potential to develop into meaningful objects for consumers. They need to serve certain psychological and symbolic functions in order to qualify as passion brands. They need to help consumers define and express their personality, combine potentially conflicting social roles or experiment with new roles. Brand passion is lived in very different ways. Some fans invest a lot of time and money in their beloved objects; others join brand communities to collectively enjoy the brand. Others yet act as missionaries on behalf of the brand or develop their own rituals in dealing with it. Companies can encourage customers' relationships with their brands by helping consumers care for the brand and enhance or maintain it. True passion, however, also needs a pinch of magic in extraordinary and unique experiences and transformations. Creating such magical moments is the true challenge for brand management.
Do Pleasant Emotional Ads Make Consumers Like Your Brand More?
Authors: Geuens Maggie , De Pelsmacker Patrick , Tuan Pham Michel 
Published: July 2014

Abstract
Emotionally pleasant TV commercials are often preferred over merely factual ones. A large-scale study of Belgian TV ads confirms this notion and shows that such commercials also create more positive feelings toward the advertised brand. Interestingly, these effects depend on neither the level of involvement associated with the product category nor the type of product. Independent of the perceived creativity of the commercial or its informational value, emotionality had a significant impact on the evaluation of a brand. However, the effects were slightly more pronounced for products that align themselves with pleasure and experience than for functional products. Advertisers should therefore leverage the power of emotions not only because these ads are better liked, but more importantly because they lead to more favorable brand attitudes.
Writ Large on Your Face: Observing Emotions Using Automatic Facial Analysis
Authors: Dieckmann Anja , Unfried Matthias 
Published: July 2014

Abstract
Emotions affect all of our daily decisions and, of course, they also influence our evaluations of brands, products and advertisements. But what exactly do consumers feel when they watch a TV commercial, visit a website or when they interact with a brand in different ways? Measuring such emotions is not an easy task. In the past, the effectiveness of marketing material was evaluated mostly by subsequent surveys. Now, with the emergence of neuroscientific approaches like EEG, the measurement of real-time reactions is possible, for instance, when watching a commercial. However, most neuroscientific procedures are fairly invasive and irritating. For an EEG, for instance, numerous electrodes need to be placed on the participant's scalp. Furthermore, data analysis is highly complex. Scientific expertise is necessary for interpretation, so the procedure remains a black box to most practitioners and the results are still rather controversial. By contrast, automatic facial analysis provides similar information without having to wire study participants. In addition, the results of such analyses are intuitive and easy to interpret even for laypeople. These convincing advantages led GfK Company to decide on facial analysis and to develop a tool suitable for measuring emotional responses to marketing stimuli, making it easily applicable in marketing research practice.
Palliative radiotherapy at the end of life: A critical review
Authors: Jones Joshua A. , Lutz Stephen T. , Chow Edward , Johnstone Peter A. 
Published: July 2014

AbstractAnswer questions and earn CME/CNEWhen delivered with palliative intent, radiotherapy can help to alleviate a multitude of symptoms related to advanced cancer. In general, time to symptom relief is measured in weeks to months after the completion of radiotherapy. Over the past several years, an increasing number of studies have explored rates of radiotherapy use in the final months of life and have found variable rates of radiotherapy use. The optimal rate is unclear, but would incorporate anticipated efficacy in patients whose survival allows it and minimize overuse among patients with expected short survival. Clinician prediction has been shown to overestimate the length of survival in repeated studies. Prognostic indices can provide assistance with estimations of survival length and may help to guide treatment decisions regarding palliative radiotherapy in patients with potentially short survival times. This review explores the recent studies of radiotherapy near the end of life, examines general prognostic models for patients with advanced cancer, describes specific clinical circumstances when radiotherapy may and may not be beneficial, and addresses open questions for future research to help clarify when palliative radiotherapy may be effective near the end of life. CA Cancer J Clin 2014;64:295–310. © 2014 American Cancer Society.
The NKG2D Ligand ULBP2 Is Specifically Regulated through an Invariant Chain–Dependent Endosomal Pathway
Authors: Uhlenbrock Franziska , Hagemann-Jensen Michael , Kehlet Stephanie , Andresen Lars , Pastorekova Silvia , Skov Søren 
Published: July 2014

Abstract
Soluble ULBP2 is a marker for poor prognosis in several types of cancer. In this study we demonstrate that both soluble and cell surface–bound ULBP2 is transported via a so far unrecognized endosomal pathway. ULBP2 surface expression, but not MICA/B, could specifically be targeted and retained by affecting endosomal/lysosomal integrity and protein kinase C activity. The invariant chain was further essential for endosomal transport of ULBP2. This novel pathway was identified through screening experiments by which methylselenic acid was found to possess notable NKG2D ligand regulatory properties. The protein kinase C inhibitor methylselenic acid induced MICA/B surface expression but dominantly blocked ULBP2 surface transport. Remarkably, by targeting this novel pathway we could specifically block the production of soluble ULBP2 from different, primary melanomas. Our findings strongly suggest that the endosomal transport pathway constitutes a novel therapeutic target for ULBP2-producing tumors.
Immobilized Immune Complexes Induce Neutrophil Extracellular Trap Release by Human Neutrophil Granulocytes via FcγRIIIB and Mac-1
Authors: Behnen Martina , Leschczyk Christoph , Möller Sonja , Batel Tobit , Klinger Matthias , Solbach Werner , Laskay Tamás 
Published: July 2014

Abstract
Canonical neutrophil antimicrobial effector mechanisms, such as degranulation, production of reactive oxygen species, and release of neutrophil extracellular traps (NETs), can result in severe pathology. Activation of neutrophils through immune complexes (ICs) plays a central role in the pathogenesis of many autoimmune inflammatory diseases. In this study, we report that immobilized ICs (iICs), which are hallmarks of several autoimmune diseases, induce the release of NETs from primary human neutrophils. The iIC-induced NET formation was found to require production of reactive oxygen species by NADPH oxidase and myeloperoxidase and to be mediated by FcγRIIIb. Blocking of the β2 integrin macrophage-1 Ag but not lymphocyte function–associated Ag-1 abolished iIC-induced NET formation. This suggests that FcγRIIIb signals in association with macrophage-1 Ag. As intracellular signaling pathways involved in iIC-induced NET formation we identified the tyrosine kinase Src/Syk pathway, which downstream regulates the PI3K/Akt, p38 MAPK, and ERK1/2 pathways. To our knowledge, the present study shows for the first time that iICs induce NET formation. Thus, we conclude that NETs contribute to pathology in autoimmune inflammatory disorders associated with surface-bound ICs.
Aerosol Vaccination with AERAS-402 Elicits Robust Cellular Immune Responses in the Lungs of Rhesus Macaques but Fails To Protect against High-Dose Mycobacterium tuberculosis Challenge
Authors: Darrah Patricia A. , Bolton Diane L. , Lackner Andrew A. , Kaushal Deepak , Aye Pyone Pyone , Mehra Smriti , Blanchard James L. , Didier Peter J. , Roy Chad J. , Rao Srinivas S. , Hokey David A. , Scanga Charles A. , Sizemore Donata R. , Sadoff Jerald C. , Roederer Mario , Seder Robert A. 
Published: July 2014

Abstract
Development of a vaccine against pulmonary tuberculosis may require immunization strategies that induce a high frequency of Ag-specific CD4 and CD8 T cells in the lung. The nonhuman primate model is essential for testing such approaches because it has predictive value for how vaccines elicit responses in humans. In this study, we used an aerosol vaccination strategy to administer AERAS-402, a replication-defective recombinant adenovirus (rAd) type 35 expressing Mycobacterium tuberculosis Ags Ag85A, Ag85B, and TB10.4, in bacillus Calmette–Guérin (BCG)-primed or unprimed rhesus macaques. Immunization with BCG generated low purified protein derivative–specific CD4 T cell responses in blood and bronchoalveolar lavage. In contrast, aerosolized AERAS-402 alone or following BCG induced potent and stable Ag85A/b-specific CD4 and CD8 effector T cells in bronchoalveolar lavage that largely produced IFN-γ, as well as TNF and IL-2. Such responses induced by BCG, AERAS-402, or both failed to confer overall protection following challenge with 275 CFUs M. tuberculosis Erdman, although vaccine-induced responses associated with reduced pathology were observed in some animals. Anamnestic T cell responses to Ag85A/b were not detected in blood of immunized animals after challenge. Overall, our data suggest that a high M. tuberculosis challenge dose may be a critical factor in limiting vaccine efficacy in this model. However, the ability of aerosol rAd immunization to generate potent cellular immunity in the lung suggests that using different or more immunogens, alternative rAd serotypes with enhanced immunogenicity, and a physiological challenge dose may achieve protection against M. tuberculosis.
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras
wild-type colorectal cancers
Authors: Chan Wing-Lok , Lee Victor Ho Fun , Siu Wai Kwan Steven , Ho Pui Ying Patty , Liu Rico King Yin , Leung To Wai 
Published: July 2014

Abstract
Background: The efficacy and safety of using combination chemotherapy with cetuximab as first-line treatment in patients with K-ras wild-type colorectal cancers has been well established. In general, weekly cetuximab was given with biweekly chemotherapy FOLFOX-4 or FOLFIRI, synchronizing them would be appealed to both patients and health care professionals. Materials and Methods: This Phase II, prospective study investigated the efficacy and safety of using biweekly cetuximab 500 mg/m 2 with chemotherapy FOLFOX-4 or FOLFIRI as first-line treatment for Chinese patients with K-ras wild-type metastatic colorectal cancer. The study endpoints included overall objective response (OR), progression-free survival (PFS), overall survival (OS) and safety. Results: Total 15 Chinese patients (male: 10 [67%]; median age: 60 [range 41-80]) were enrolled. Patients received median 12 cycles (range 2-12) of chemotherapy + cetuximab (FOLFOX-4 + cetuximab: 9 [60%]; FOLFIRI + cetuximab: 6 [40%]). Six patients (40%) with non-progressive disease after 12 cycles of chemotherapy + cetuximab carried on maintenance cetuximab. Median duration of follow-up (FU) was 23.7 months. The OR was 40% (complete response: 0%; partial response: 40%) for a disease control rate of 87%. Median PFS and OS were 7.8 months and 17.9 months respectively. For maintenance cetuximab phase, median PFS since the start of maintenance cetuximab was 6.8 months and median OS was 17.0 months. The only grade 3-4 toxicities were neutropenia (26.7%) in chemotherapy phase and acneiform rashes (16.7%) in maintenance phase. Conclusions: Biweekly cetuximab with combination chemotherapy was effective and safe as weekly dose. Further studies are warranted for the role of maintenance cetuximab.
Tolvaptan
Authors: Rangarajan Bharath , Binoy Vineetha , Hingmire Sachin Sharatchandra , Noronha Vanita 
Published: July 2014

AbstractHyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan. Vaptans including Tolvaptan act as "aquaretic" agents cousing excretion of water while retaining the sodium. Administration of this agent for prescribed periods result in improvement of serum sodium levels. The drug can be used in many clinical situations resulting in hyponatremia including congestive heart failure, cirrhosis and syndrome of inappropriate ADH secretion (SIADH) including SIADH related to malignancies.